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1210Revascularization in Patients With
Multivessel Coronary Artery Disease and
Chronic Kidney DiseaseEverolimus-Eluting Stents Versus
Coronary Artery Bypass Graft SurgeryABSTRACTBACKGROUND Randomized trials of percutaneous coronary intervention (PCI) versus coronary artery bypass graft
(CABG) routinely exclude patients with chronic kidney disease (CKD).
OBJECTIVES This study evaluated outcomes of PCI versus CABG in patients with CKD.
METHODS Patients with CKD who underwent PCI using everolimus-eluting stents were propensity-score matched to
patients who underwent isolated CABG for multivessel coronary disease in New York. The primary outcome was all-cause
mortality. Secondary outcomes were myocardial infarction (MI), stroke, and repeat revascularization.
RESULTS Of 11,305 patients with CKD, 5,920 patients were propensity-score matched. In the short term, PCI was
associated with a lower risk of death (hazard ratio [HR]: 0.55; 95% conﬁdence interval [CI]: 0.35 to 0.87), stroke
(HR: 0.22; 95% CI: 0.12 to 0.42), and repeat revascularization (HR: 0.48; 95% CI: 0.23 to 0.98) compared with CABG.
In the longer term, PCI was associated with a similar risk of death (HR: 1.07; 95% CI: 0.92 to 1.24), higher risk of MI
(HR: 1.76; 95% CI: 1.40 to 2.23), a lower risk of stroke (HR: 0.56; 95% CI: 0.41 to 0.76), and a higher risk of repeat
revascularization (HR: 2.42; 95% CI: 2.05 to 2.85). In the subgroup with complete revascularization with PCI, the
increased risk of MI was no longer statistically signiﬁcant (HR: 1.18; 95% CI: 0.67 to 2.09). In the 243 matched pairs
of patients with end-stage renal disease on hemodialysis, PCI was associated with signiﬁcantly higher risk of death
(HR: 2.02; 95% CI: 1.40 to 2.93) and repeat revascularization (HR: 2.44; 95% CI: 1.50 to 3.96) compared with CABG.
CONCLUSIONS In patients with CKD, CABG is associated with higher short-term risk of death, stroke, and repeat
revascularization, whereas PCI with everolimus-eluting stents is associated with a higher long-term risk of repeat
revascularization and perhaps MI, with no long-term mortality difference. In the subgroup on dialysis, the results favored
CABG over PCI. (J Am Coll Cardiol 2015;66:1209–20) © 2015 by the American College of Cardiology Foundation.SEE PAGE 1221
T he chronic kidney disease (CKD) populationhas grown exponentially over the pastdecade and is projected to grow consistently
in the next decade due to an increase in the incidence
of obesity and diabetes and a decrease in mortality
rates (1). Cardiovascular disease is the leading cause
of morbidity and mortality in patients with CKD
(1,2). However, there is a “treatment risk paradox,”
in that these high-risk patients have lower rates of
medical therapy, referral for stress testing, cardiac
catheterization, and revascularization compared
with low-risk patients (2). Moreover, the majority of
cardiovascular clinical trials routinely exclude this
high-risk group of patients (3). The evidence-based
management of these patients, therefore, relies on
extrapolating the results from clinical trials in non-
CKD cohorts and applying them to patients withCKD. However, it is not known whether this extrapo-
lation is accurate.In patients with obstructive coronary artery dis-
ease (CAD), percutaneous coronary intervention (PCI)
and coronary artery bypass graft (CABG) surgery are
both treatment options. Although a number of clinical
trials have been performed to evaluate the efﬁcacy
and safety of PCI versus CABG, patients with CKD
have generally been excluded. The 2014 European
Society of Cardiology and the European Association
for Cardio-Thoracic Surgery Guidelines on myocardial
revascularization recommend CABG over PCI (Class IIa)
in patients with moderate to severe CKD and multivessel
disease when the surgical risk proﬁle is acceptable and
life expectancy is more than 1 year (4). The American
FIGURE 1 EES Versus CABG for Longer-Term Risk of Death
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In the propensity score–matched cohort of patients who underwent either percutaneous
coronary intervention with EES or CABG, there was no statistically signiﬁcant difference in
death between the 2 cohorts. CABG ¼ coronary artery bypass graft; EES ¼ everolimus-
eluting stent(s).
AB BR E V I A T I O N S
AND ACRONYM S
CABG = coronary artery bypass
graft
CAD = coronary artery disease
CI = conﬁdence interval
CKD = chronic kidney disease
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
eGFR = estimated glomerular
ﬁltration rate
HR = hazard ratio
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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guidelines also recommend CABG to improve survival in
patients with end-stage renal disease and 3-vessel CAD
or proximal left anterior descending artery plus 1 other
major vessel (5). Most of these recommendations stem
from observational studies of CABG versus PCI using
older-generation stents. In the absence of randomized
trials comparing CABG and PCI with second-generation
drug-eluting stents (DES) in patients with CKD, we used
data from the New York State registries to compare out-
comes for CABG and PCI in patients with CKD.
METHODS
STUDY POPULATION. Patients with CKD who un-
derwent either PCI with everolimus-eluting stents
(EES) or isolated CABG surgery for multivessel CAD
between January 1, 2008, and December 31, 2011, in
New York State were included in the study. Patients
were identiﬁed using the New York State Percuta-
neous Coronary Intervention Reporting System and
the Cardiac Surgery Reporting System registries.
These are mandatory reporting systems for all PCI
and CABG procedures performed in nonfederal hos-
pitals in New York State. Data are entered by trained
data coordinators at participating hospitals. Audits of
samples of medical records are conducted regularly to
ensure data quality.
PATIENT INCLUSION AND EXCLUSION CRITERIA.
The inclusion criteria were the following: 1) patients
with CKD, deﬁned as those with an estimated
glomerular ﬁltration rate (eGFR) (calculated using the
MDRD [Modiﬁcation of Diet in Renal Disease] study
equation) <60 ml/min/1.73 m2; 2) patients with mul-
tivessel disease, deﬁned as severe stenosis ($70%) in
at least 2 major epicardial coronary arteries; and
3) patients undergoing PCI with implantation of EES
or those undergoing isolated CABG.
The exclusion criteria were the following: 1) pre-
vious cardiac surgery (CABG or valve surgery),
because such patients are unlikely to undergo repeat
surgery; 2) myocardial infarction (MI) within 24 h
preceding the index procedure, because these pa-
tients preferentially undergo PCI; 3) severe left main
CAD (degree of stenosis $50%), because these pa-
tients preferentially undergo CABG; 4) PCI with a
stent other than an EES or using a combination of
stents; 5) revascularization within 1 year before the
index procedure; and 6) unstable hemodynamics or in
cardiogenic shock.
PATIENT FOLLOW-UP. The Percutaneous Coronary
Intervention Reporting System and Cardiac Surgery
Reporting System registries collect data on in-hospital
events and are linked across time and with each otherto capture subsequent revascularization pro-
cedures. In addition, the registries were
linked with the New York State Vital Statistics
registry to obtain information on mortality
and with the Statewide Planning and Research
Cooperative System registry to obtain follow-
up information for patients admitted with MI
and stroke. The Statewide Planning and
Research Cooperative System registry collects
comprehensive information on discharges
from all nonfederal hospitals in New York
State and contains information on patient
diagnoses, procedures, admission and dis-
charge dates, and discharge disposition for
hospital discharges, ambulatory surgery, and
emergency department admissions. Data are
edited monthly to identify errors, audit re-
ports are generated after monthly updates, and
related data are veriﬁed using 2 data sources for con-
sistency (6).
OUTCOMES. The primary outcome of the study was
long-term all-cause death. Secondary outcomes were
MI, stroke, and repeat revascularization, which were
tabulated separately. Short-term (within 30 days) and
longer-term outcomes were evaluated. MI included
both procedural MI (deﬁned as new Q waves in both
the Percutaneous Coronary Intervention Reporting
System and the Cardiac Surgery Reporting System)
and spontaneous MI (deﬁned as an emergency
admission with a principal diagnosis of MI or a
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ondary diagnosis of MI). Similarly, stroke was iden-
tiﬁed either as a complication at the time of the index
procedure or at readmission (principal diagnosis
of stroke). Repeat revascularization was identiﬁed
as any unstaged revascularization after the index
procedure. Staged revascularization was deﬁned as a
nontarget vessel revascularization within 90 days of
the index procedure that was coded as intended to be
staged in the index procedure and at the time of the
staged procedure.
STATISTICAL ANALYSIS. Propensity-score matching.
To adjust for differences in measured baseline
characteristics between the PCI and CABG groups
and to assemble a cohort of patients with similar
baseline characteristics, propensity-score matching
was used. The propensity score is a conditional
probability of having a particular exposure (EES vs.
CABG), given a set of baseline-measured covariates
(7,8). A nonparsimonious multivariable logistic
regression model (9), using EES use as the depen-
dent variable and all of the baseline characteristics
outlined in Table 1 as covariates, was used toTABLE 1 Baseline Characteristics Before and After Propensity-Score
Pre-Matching
EES
(n ¼ 5,058)
CABG
(n ¼ 6,247)
Age, yrs 70.21  10.60 69.13  10.3
<59 17.16 18.20
60–69 26.59 28.37
70–79 35.77 37.14
$80 20.48 16.30
Body surface area, m2 2.00  0.27 2.02  0.27
Sex
Male 60.50 64.80
Female 39.50 35.20
Hispanic 13.15 8.90
Race
White 78.39 85.51
Black 11.05 7.88
Other 10.56 6.61
Smoking 26.69 26.12
Diabetes mellitus 47.57 48.97
Hypertension 75.58 77.70
Hyperlipidemia 63.54 60.30
Previous PCI 35.03 17.72
Unstable angina 20.32 19.72
Ejection fraction, %
<20 0.81 2.19
20–29 4.74 8.58
30–39 6.68 13.57
40–49 12.77 19.63
$50 68.70 55.50
Missing 6.29 0.53estimate the propensity scores. Matching was per-
formed using a 1:1 matching protocol without
replacement (Greedy matching algorithm), using a
caliper width equal to 0.2 of the SD of the logit of the
propensity score. Absolute standardized differences
were estimated for all baseline covariates before and
after matching to assess pre-match and post-match
imbalances (10). Absolute standardized differences
<10% for a given covariate indicate a relatively small
imbalance (10). The risks of outcomes were analyzed
in the matched cohort using a Cox proportional
regression model after stratifying the matched pairs.
Subgroup analyses . Pre-speciﬁed subgroup ana-
lyses were performed on the basis of anatomy:
1) 3-vessel disease versus 2-vessel disease; and
2) complete versus incomplete revascularization in
the PCI cohort. For the subgroup analysis, only the
corresponding matched pairs in a subgroup were
chosen to maintain the baseline balance between EES
and CABG groups. In addition, a pre-speciﬁed anal-
ysis was performed of the cohort of patients on dial-
ysis. Subgroup analysis using corresponding matched
pairs of patients on dialysis yielded a small sampleMatching
Post-Matching
ASD*
EES
(n ¼ 2,960)
CABG
(n ¼ 2,960) ASD*
2 10.30 69.94  10.67 69.62  10.53 3.00
2.70 18.00 17.80 0.60
4.00 26.40 26.80 1.00
2.90 36.70 36.30 0.80
10.80 18.90 19.10 0.50
5.80 2.00  0.27 2.00  0.27 0.10
8.90 62.00 61.50 1.00
8.90 38.00 38.50 1.00
13.60 12.00 11.20 2.50
18.60 81.30 81.50 0.40
10.90 9.80 10.10 1.20
14.10 8.90 8.40 1.90
1.30 26.40 26.80 1.10
2.80 48.90 48.30 1.20
5.00 77.00 78.20 2.80
6.70 62.40 63.30 1.90
40.10 26.30 25.60 1.70
1.50 20.30 20.50 0.60
11.40 1.20 1.20 0.30
15.40 6.60 6.60 0.10
23.00 9.40 9.30 0.20
18.70 16.80 16.10 1.70
27.50 65.30 65.70 0.90
32.10 0.80 1.10 2.50
Continued on the next page
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was performed by ﬁrst choosing patients on dialysis
from the unmatched cohort of patients and then
matching them on their baseline measure covariates,
as described earlier. In addition, in the cohort not on
dialysis (separate propensity-score matching), sub-
group analyses were performed to evaluate the out-
comes on the basis of eGFR categories of 45 to 60,
30 to 45, 15 to 30, and <15 ml/min. However, the
number of patients in the eGFR <15 and eGFR 15 to 30
categories was small, and this group was combined
with the eGFR 30 to 45 category.
All reported p values are 2-sided and are not
adjusted for multiple testing. All analyses were per-
formed with SAS version 9.3 (SAS Institute, Cary,
North Carolina). The event rates presented are
Kaplan-Meier estimates.
RESULTS
We identiﬁed 11,305 patients with CKD and multi-
vessel disease who fulﬁlled the entry criteria (Table 1,
Online Table 1). Of the patients, 5,058 (45.0%)TABLE 1 Continued
Pre-Matching
EES
(n ¼ 5,058)
CABG
(n ¼ 6,247)
Previous MI
Within 1–7 days 16.01 19.51
Within 8–14 days 2.17 7.89
Within 15–20 days 0.55 1.38
>20 days 19.24 23.16
No previous MI 62.02 48.06
Cerebrovascular disease 3.70 9.48
COPD 7.26 13.53
Peripheral arterial disease 13.66 17.00
Congestive heart failure
None 87.52 74.68
At current admission 7.85 20.55
Before current admission 4.63 4.77
Malignant ventricular arrhythmia 0.51 1.23
Previous PCI 87.52 74.68
eGFR categories
30 #eGFR <60 84.12 81.21
15 #eGFR <30 6.88 9.65
eGFR <15 0.73 1.01
Dialysis 8.26 8.13
No. of diseased vessels
2, with proximal LAD 18.25 17.03
2, without proximal LAD 52.77 15.26
3, with proximal LAD 10.16 35.92
3, without proximal LAD 18.82 31.79
Values are mean  SD or % unless otherwise indicated. *ASD <10% denotes relatively
ASD ¼ absolute standardized difference; CABG ¼ coronary artery bypass graft; CO
eGFR ¼ estimated glomerular ﬁltration rate; LAD ¼ left anterior descending artery; MIunderwent PCI with EES and 6,247 patients (55.0%)
underwent CABG. The cohort included 48.0% with
diabetes and 8.2% on dialysis (Table 1). Using
propensity-score matching, 2,960 PCI patients were
matched with 2,960 CABG patients with similar pro-
pensity scores. After matching, the absolute stan-
dardized difference was <10.0% for all variables,
indicating an adequate match and no signiﬁcant
baseline difference between the 2 groups (Table 1).
The C statistic for the model was 0.81. All outcomes
presented in the following sections are for the
matched cohort.
SHORT-TERM (WITHIN 30 DAYS) OUTCOMES. In the
5,920 patients in the matched cohort, PCI was
associated with a 45.0% lower risk of death (1.0%
vs. 1.7%; hazard ratio [HR]: 0.55; 95% conﬁdence
interval [CI]: 0.35 to 0.87; p ¼ 0.01), a 78.0% lower
risk of stroke (0.4% vs. 1.7%; HR: 0.22; 95% CI: 0.12
to 0.42; p < 0.0001), and a 52.0% lower risk
of repeat revascularization (0.4% vs. 0.8%; HR:
0.48; 95% CI: 0.23 to 0.98; p ¼ 0.04) with no sig-
niﬁcant difference in MI when compared with CABG
(Table 2).Post-Matching
ASD*
EES
(n ¼ 2,960)
CABG
(n ¼ 2,960) ASD*
9.20 17.20 17.40 0.40
26.40 3.10 3.20 0.80
8.40 0.90 0.80 0.70
9.60 21.60 21.20 0.80
28.40 57.30 57.40 0.20
23.50 5.30 5.60 1.30
20.70 9.20 9.60 1.20
9.30 14.80 15.60 2.40
33.30 83.20 83.40 0.60
37.00 11.60 11.70 0.30
0.70 5.30 4.90 1.50
7.70 0.70 0.60 0.80
33.30 27.35 27.27 0.20
7.70 83.38 82.91 1.30
10.10 7.53 7.84 1.10
3.00 0.78 0.88 1.10
0.50 8.31 8.38 0.20
3.20 23.90 23.80 0.30
86.20 30.10 30.10 0.10
64.30 16.80 17.40 1.40
30.20 29.10 28.80 0.70
small imbalance.
PD ¼ chronic obstructive pulmonary disease; EES ¼ everolimus-eluting stent(s);
¼ myocardial infarction; PCI ¼ percutaneous coronary intervention.
TABLE 2 Short- and Long-Term Outcomes in the
Propensity Score–Matched Cohort
Outcome
No. of
Events
Event Rate
(KM Estimate)
Hazard Ratio
(95% CI) p Value
Short-term outcomes
Death
EES 29 1.0 0.55 (0.35–0.87) 0.01
CABG 51 1.7 Reference
MI
EES 20 0.7 1.33 (0.68–2.60) 0.40
CABG 15 0.5 Reference
Stroke
EES 11 0.4 0.22 (0.12–0.42) <0.0001
CABG 50 1.7 Reference
Repeat revascularization
EES 11 0.4 0.48 (0.23–0.98) 0.04
CABG 23 0.8 Reference
Long-term outcomes
Death
EES 458 22.7 1.07 (0.92–1.24) 0.40
CABG 469 20.5 Reference
MI
EES 233 10.7 1.76 (1.4–2.23) <0.0001
CABG 153 7.0 Reference
Stroke
EES 90 4.5 0.56 (0.41–0.76) 0.0002
CABG 143 6.4 Reference
Repeat revascularization
EES 582 26.1 2.42 (2.05–2.85) <0.0001
CABG 284 13.1 Reference
CI ¼ conﬁdence interval; KM¼ Kaplan-Meier; MI¼myocardial infarction; other abbreviations as in
Table 1.
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PCI was associated with a similar risk of death
(22.7% vs. 20.5%; HR: 1.07; 95% CI: 0.92 to 1.24;
p ¼ 0.40) compared with CABG at a mean follow-up of
2.9 years (2.7 years for EES and 3.2 years for CABG)
(Figure 1, Table 2). This was consistent across
anatomic subgroups on the basis of the number of
diseased vessels and completeness of revasculariza-
tion (pinteraction >0.05) (Table 3). In addition, in the
cohort not on dialysis, subgroup analysis on the basis
of eGFR categories yielded largely similar results
(pinteraction >0.05) (Table 4).
Myocard ia l in farct ion . PCI was associated with a
higher risk of MI (10.7% vs. 7.0%; HR: 1.76; 95% CI:
1.40 to 2.23; p < 0.0001) compared with CABG
(Figure 2, Table 2). This was driven by patients with
3 diseased vessels (HR: 2.75; 95% CI: 1.55 to 4.87;
p ¼ 0.0005), but not those with 2 diseased vessels
(HR: 1.26; 95% CI: 0.76 to 2.09; p ¼ 0.37) (pinteraction ¼
0.04), and by patients who underwent incomplete
revascularization (HR: 1.91; 95% CI: 1.48 to 2.47;
p < 0.0001), but not those who underwent completerevascularization (HR: 1.18; 95% CI: 0.67 to 2.09;
p ¼ 0.56), although the test for interaction for the
latter was not signiﬁcant (pinteraction ¼ 0.13) (Table 3).
In addition, in the cohort not on dialysis, subgroup
analysis on the basis of eGFR categories yielded
largely similar results (pinteraction ¼ 0.94) (Table 4).
Stroke . PCI was associated with a lower risk of stroke
(4.5% vs. 6.4%; HR: 0.56; 95% CI: 0.41 to 0.76;
p ¼ 0.0002) compared with CABG (Figure 3, Table 2).
In addition, in the cohort not on dialysis, subgroup
analysis on the basis of eGFR categories yielded
largely similar results (Table 4).
Repeat revascu lar i zat ion . PCI was associated with
a higher risk of repeat revascularization (26.1% vs.
13.1%; HR: 2.42; 95% CI: 2.05 to 2.85; p < 0.0001)
compared with CABG (Figure 4, Table 2). The results of
the test for interaction was borderline signiﬁcant
(pinteraction ¼ 0.05) for the magnitude of effect size,
rather than the direction, both for the number of
diseased vessels and for the completeness of revas-
cularization. Thus, the risk of repeat revascularization
with PCI (vs. CABG) was signiﬁcantly higher in those
with 3-vessel disease (vs. 2-vessel disease) and in
those with incomplete revascularization (vs. complete
revascularization) (Table 3). In addition, in the cohort
not on dialysis, subgroup analysis on the basis of eGFR
categories yielded largely similar results (Table 4).
PATIENTS ON DIALYSIS. A separate propensity
score matching was performed in patients on dial-
ysis who would otherwise satisfy all of the inclusion
and exclusion criteria. Propensity-score matching
identiﬁed 486 patients on dialysis with similar
baseline characteristics. In the matched cohort of
patients on dialysis, PCI was associated with a
signiﬁcantly higher long-term risk of death (54.3%
vs. 39.1%; HR: 2.02; 95% CI: 1.40 to 2.93; p ¼
0.0002), a numerically higher risk of MI (31.9% vs.
16.7%; HR: 1.68; 95% CI: 0.99 to 2.85; p ¼ 0.05), a
signiﬁcantly higher risk of repeat revascularization
(48.3% vs. 25.0%; HR: 2.44; 95% CI: 1.50 to 3.96;
p ¼ 0.0003), and no difference in stroke compared
with CABG (Table 5).
DISCUSSION
The results of this study of 5,920 subjects with CKD and
multivessel disease showed that PCI using the latest-
generation stents (EES) was associated with lower
short-term risk (death, stroke, and repeat revascu-
larization), similar long-term risk of death, a higher
risk ofMI (in thosewith incomplete revascularization),
and a lower risk of stroke, but a higher risk of repeat
revascularization compared with CABG (Central
Illustration). However, in the subgroup on dialysis,
TABLE 3 Risk of Primary and Secondary Outcomes in Anatomic Subgroups
No. of
Patients
No. of
Events
Event Rate (%)
(KM Estimate)
Hazard Ratio
(95% CI) p Value
p Value for
Interaction
Outcome: death
3 diseased vessels 0.23
EES 541 95 24.7 1.15 (0.81–1.61) 0.44
CABG 541 93 24.0 Reference
2 diseased vessels
EES 779 88 17.7 0.86 (0.61–1.19) 0.35
CABG 779 108 18.1 Reference
Outcome: MI
3 diseased vessels 0.04
EES 541 51 13.8 2.75 (1.55–4.87) 0.0005
CABG 541 24 6.1 Reference
2 diseased vessels
EES 779 45 8.0 1.26 (0.76–2.09) 0.37
CABG 779 36 6.3 Reference
Outcome: repeat revascularization
3 diseased vessels 0.05
EES 541 125 32.0 3.75 (2.47–5.69) <0.0001
CABG 541 44 10.4 Reference
2 diseased vessels
EES 779 134 22.2 2.18 (1.56–3.03) <0.0001
CABG 779 68 12.5 Reference
Outcome: death
Complete revascularization 0.89
EES 541 72 16.9 1.09 (0.76–1.58) 0.64
CABG 541 74 18.4 Reference
Incomplete revascularization*
EES 2,419 386 23.9 1.06 (0.90–1.25) 0.48
CABG 2,419 395 21.0 Reference
Outcome: MI
Complete revascularization 0.13
EES 541 33 8.3 1.18 (0.67–2.09) 0.56
CABG 541 33 8.56 Reference
Incomplete revascularization*
EES 2,419 200 11.2 1.91 (1.48–2.47) <0.0001
CABG 2,419 120 6.5 Reference
Outcome: repeat revascularization
Complete revascularization 0.05
EES 541 79 19.8 1.68 (1.13–2.48) 0.01
CABG 541 61 15.9 Reference
Incomplete revascularization*
EES 2,419 503 27.5 2.60 (2.17–3.13) <0.0001
CABG 2,419 223 12.4 Reference
*On the basis of incomplete revascularization in the PCI group.
Abbreviations as in Tables 1 and 2.
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1215the results favored CABG over PCI, with an increase in
death and repeat revascularization with PCI.
REVASCULARIZATION IN PATIENTS WITH CKD.
Patients with CKD are at high risk of cardiovascular
disease and have an increased risk of death from CAD.
Although the major concern in patients with CAD and
CKD is to prevent/avoid acute kidney injury (during
PCI or CABG), CKD patients are 5 to 10 times more
likely to die (mainly of cardiovascular causes) thanexperience the development of end-stage renal dis-
ease requiring dialysis (10,11). In a longitudinal
follow-up of a large managed-care organization, Keith
et al. (11) reported that the rate of end-stage renal
disease was only 1.3%, whereas patients were more
likely to die, with a mortality rate of 24.3%.
CAD in CKD patients tends to present with unique
challenges, including earlier onset, more rapid pro-
gression, and stronger association with calciﬁcation
TABLE 4 Subgroup Analyses on the Basis of eGFR Categories in Subjects Not on Dialysis
No. of
Patients
No. of
Events
Event
Rates*
Hazard Ratio
(95% CI) p Value
p Value for
Interaction
Outcome: death 0.15
eGFR <45
EES 395 61 21.74 0.71 (0.49–1.03) 0.07
CABG 395 83 25.95 Reference
eGFR 45–60
EES 1,073 99 14.4 1.01 (0.74–1.38) 0.94
CABG 1,073 109 13.0 Reference
Outcomes: MI 0.96
eGFR <45
EES 395 26 8.64 1.75 (0.86–3.56) 0.12
CABG 395 14 4.73 Reference
eGFR 45–60
EES 1,073 60 7.56 1.79 (1.12–2.84) 0.01
CABG 1,073 37 4.5 Reference
Outcome: stroke 0.20
eGFR <45
EES 395 14 4.95 0.71 (0.34–1.48) 0.36
CABG 395 20 6.31 Reference
eGFR 45-60
EES 1,073 18 2.4 0.37 (0.20–0.70) 0.002
CABG 1,073 43 4.9 Reference
Outcome: repeat
revascularization
0.58
eGFR <45
EES 395 68 22.32 1.69 (1.04–2.75) 0.03
CABG 395 32 11.15 Reference
eGFR 45–60
EES 1,073 200 24.9 1.98 (1.51–2.58) <0.0001
CABG 1,073 114 14.2 Reference
*Kaplan-Meier estimate.
Abbreviations as in Tables 1 and 2.
FIGURE 2 EES Versus CABG for Longer-Term Risk of MI
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In the propensity score–matched cohort of patients, there was a higher risk of MI in the
cohort who underwent percutaneous coronary intervention with EES compared with those
who underwent CABG. In the subgroup of patients who underwent complete revascular-
ization with percutaneous coronary intervention, the increased risk of MI was no longer
statistically signiﬁcant (hazard ratio: 1.18; 95% conﬁdence interval: 0.67 to 2.09).
MI ¼ myocardial infarction; other abbreviations as in Figure 1.
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1216and vascular stiffness. As such, revascularization
with PCI or CABG poses challenges. Compared with
patients without CKD, patients with CKD have
increased rates of repeat revascularization after PCI
with bare-metal stents (12–15), although these rates
have improved considerably compared with balloon
angioplasty alone (16). With the advent of DES, the
incidence of restenosis after PCI has further
decreased compared with bare-metal stents in the
nondialysis CKD population (17), as well as for pa-
tients on dialysis (18–23). However, most of the evi-
dence is from nonrandomized studies (11). In
addition, both PCI and CABG are associated with an
increased risk of acute kidney injury, with some
studies showing a 2- to 3-fold higher risk with CABG
in the short term than with PCI (24).
The question of PCI versus CABG in patients with
multivessel disease and CKD is not readily answered
by randomized trials because the majority of ran-
domized trials of PCI versus CABG have either
excluded patients with CKD or included only a small
subgroup of such patients. In the SYNTAX study
(TAXUS Drug-Eluting Stent Versus Coronary Artery
Bypass Surgery for the Treatment of Narrowed
Arteries) of CABG versus PCI using paclitaxel-eluting
stents (25), only 264 patients with renal insufﬁciency
(eGFR <60) were included. In this small subgroup of
patients, CABG was superior to PCI for the reduction of
cardiovascular events (15.6% vs. 27.4%; p < 0.05),
driven by a decrease in repeat revascularization (5.0%
vs. 14.9%; p < 0.05), with no difference in death (9.9%
vs. 11.8%) (26). Compared with the ﬁrst-generation
DES used in the SYNTAX study, second-generation
DES (such as EES) have thinner struts and thinner
and more biocompatible polymer properties that
reduce inﬂammation, promote faster vessel healing,
and reduce the risk of restenosis and stent thrombosis.
As such, data from an all-comers population from
randomized, controlled trials (27), observational reg-
istries (28), and meta-analyses of randomized trials
(27,29) indicate a reduction in death, MI, and stent
thrombosis with newer-generation stents compared
with older-generation stents. Data on the CKD cohort
suggest similar low rates of repeat revascularization
with EES, even compared with the cohort with no CKD
(30). In the BEST (Bypass Surgery Versus Everolimus-
Eluting Stent Implantation for Multivessel Coronary
Artery Disease) study (31), PCI with EES was associated
with increased risk of MI and repeat revasculariza-
tion, without any mortality difference compared with
CABG, largely similar to our report on the overall
cohort from the New York State registries (32). How-
ever, the BEST study did not report on the CKD
subgroup.
FIGURE 3 EES Versus CABG for Longer-Term Risk of Stroke
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In the propensity score–matched cohort of patients, there was a lower risk of stroke in
the cohort who underwent percutaneous coronary intervention with EES compared with
those who underwent CABG. Abbreviations as in Figure 1.
TABLE 5 Primary and Secondary Outcomes in Patients on
Dialysis
Outcomes
No. of
Patients
No. of
Events
Event
Rate,
%*
Hazard Ratio
(95% CI)
p
Value
Death
EES 243 98 54.3 2.02
(1.40–2.93)
0.0002
CABG 243 69 39.1 Reference
MI
EES 243 52 31. 9 1.68
(0.99–2.85)
0.05
CABG 243 30 16.7 Reference
Stroke
EES 243 12 10.7 1.17
(0.39–3.47)
0.78
CABG 243 7 4.1 Reference
Repeat
revascularization
EES 243 79 48.3 2.44
(1.50–3.96)
0.0003
CABG 243 39 25.0 Reference
*Kaplan-Meier estimate.
Abbreviations as in Tables 1 and 2.
FIGURE 4 EES Versus CABG for the Longer-Term Risk of Repeat Revascularization
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In the propensity score–matched cohort of patients, there was a higher risk of repeat
revascularization in the cohort who underwent percutaneous coronary intervention with
EES compared with those who underwent CABG. Abbreviations as in Figure 1.
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1217The results of this study with data from 5,920
propensity score–matched patients therefore offer
important insights into the outcomes of patients who
underwent PCI with the latest-generation DES (EES)
or CABG. For the overall CKD cohort, PCI using EES
was associated with lower short-term risk (death,
stroke, and repeat revascularization) compared with
CABG, consistent with the results of previous studies.
In addition, the primary outcome of death in the
longer term was also not statistically different be-
tween PCI and CABG. PCI was associated with a
higher risk of MI (in those with incomplete revascu-
larization) and repeat revascularization compared
with CABG. The higher risk of MI in those with
incomplete revascularization with PCI is an important
outcome because patients on dialysis who present
with an MI have high mortality from a cardiac cause
and poor long-term survival (33). In a recent analysis
of 1,786 propensity score–matched patients with CKD
from Ontario, Canada, CABG was associated with
improved survival compared with PCI using DES (34).
However, the study did not report outcomes with
second-generation DES. Our study has 3.3 the
sample size of the Ontario analysis and restricts the
comparison to second-generation DES (EES). Conse-
quently, it offers important additional insights and is
also the largest series comparing CABG with second-
generation DES. Although there was excess stroke
occurrence with CABG compared with PCI in the
current study, consistent with previous data, more
recent trials have shown the risk of stroke to besimilar to that for CABG and PCI (31), likely due to
increased use of off-pump surgery and avoidance of
aortic cross-clamping.
In our study, the results favored CABG over PCI in
the subgroup on dialysis, with increases in death,
repeat revascularization, and numerically higher
MIs with PCI. The results for the dialysis cohort
are consistent with data from the CREDO-Kyoto PCI/
CABG registry analysis of 388 patients on dialysis,
CENTRAL ILLUSTRATION CABG Versus PCI in Patients With CKD and Multivessel Coronary Artery Disease
Stroke (ST)
 PCI                                                                                                                                                                                  CABG
ST = Short-term (30 days)
LT = Longer-term
* In those with incomplete revascularization
Repeat Revascularization (LT)
5,920 patients with eGFR <60 and multivessel disease
       MI* (LT)                                                                                                                                                                        Death (ST)
Death (LT)
Bangalore, S. et al. J Am Coll Cardiol. 2015; 66(11):1209–20.
In 5,920 patients with CKD and multivessel disease, CABG was associated with higher upfront risk of death and stroke, whereas PCI with the latest-generation
drug-eluting stent (everolimus-eluting stent) was associated with an increased risk of repeat revascularization and MI (in those with incomplete revascularization).
CABG ¼ coronary artery bypass graft; CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate; LT ¼ longer term; MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention; ST ¼ short term (30 days).
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1218in which CABG was associated with a lower risk of
cardiac death, MI, and repeat revascularization
compared with PCI using bare-metal stents or ﬁrst-
generation DES, although there was no difference in
all-cause death between the 2 groups (35). However,
other studies comparing CABG with PCI using ﬁrst-
generation DES (N ¼ 104 patients) have shown a
lower risk of both all-cause death and cardiac
death with CABG in patients on hemodialysis (36). The
results are also consistent with the analysis by Shroff
et al. (37), where short-term mortality was higher after
CABG, but long-term survival was superior. However,
the study by Shroff et al. (37) did not directly compare
CABG with PCI, and PCI was performed mainly using
ﬁrst-generation DES. Patients with CKD, especially
patients on dialysis, have an increased prevalence of
medial calciﬁcation (38). This impairs the response toPCI, with increased prevalence of underexpanded
stents, reduced efﬁcacy of the antiproliferative drugs
eluted from the stent, and impaired endothelializa-
tion, resulting in a propensity for restenosis and stent
thrombosis. The newer-generation DES, and especially
EES, have thinner struts as well as thinner, more
biocompatible and thromboresistant polymers (39).
Although stenting results in “spot” treatment, the risk
of restenosis and stent thrombosis in the stented
segment contributes to a proportion of long-term
events with PCI. EES, with all of the favorable
properties mentioned earlier, likely reduce future
stent-associated events and can potentially bridge the
outcomes gap between PCI and CABG.
Although the present study compared PCI and
CABG, it is not known whether revascularization is
superior to optimal medical therapy alone in patients
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: In patients with CKD, CABG was associated with a
higher 30-day risk of death, stroke, and repeat revascularization
compared with PCI with EES, whereas stenting was associated
with a higher long-term risk of repeat revascularization and
MI when revascularization was incomplete.
TRANSLATIONAL OUTLOOK: Further studies are needed to
determine predictors of outcomes in patients with CKD under-
going myocardial revascularization to guide referrals for CABG or
PCI.
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1219with CKD because patients with CKD were excluded
or formed a small proportion of enrolled patients in
contemporary trials of revascularization versus opti-
mal medical therapy. The ISCHEMIA CKD (ISCHEMIA-
Chronic Kidney Disease) trial (NCT01985360) will
address the question of invasive versus conservative
management in patients with advanced CKD and will
provide valuable insights into this question.
STUDY LIMITATIONS. In our analysis, although
propensity-score matching adjusts for baseline im-
balances, the analysis does not control for unmea-
sured confounders. We did not have data on
medication use for the 2 cohorts. The analysis
compared CABG with PCI using EES, and hence, the
results may not be generalizable to other second-
generation DES. Moreover, the cohort on dialysis
was a small subgroup of patients and the analysis is
likely underpowered. Although there was no differ-
ence in mortality between PCI and CABG for the
overall CKD cohort, a difference may appear at
longer-term follow-up. The registries do not collect
data on the method used to measure serum creati-
nine, nor whether the method was standardized to
isotope dilution mass spectrometry. However, this is
unlikely to differentially affect the PCI and CABG
outcomes. Similarly, although the Modiﬁcation of
Diet in Renal Disease formula was used to calculate
the eGFR, the choice of formula is unlikely to differ-
entially affect the PCI and CABG outcomes. The
follow-up outcomes were derived from registries in
New York State, and patients who had outcomes
outside of New York State would likely have been
missed. However, a previous study evaluated the
percentage of deaths missed because of the previ-
ously mentioned limitation and found it to be small
(40) and unlikely to differentially affect the PCI and
CABG outcomes. We excluded patients with left main
artery disease. In the timeframe of this study, PCI for
left main artery disease was a Class III indication by
the American College of Cardiology/American Heart
Association guideline committee. As such, only 159
patients with left main disease underwent PCI,
whereas the majority (2,715 patients) underwent
CABG. Given the small numbers and likely selection
bias in those who underwent PCI in deference tothe Class III recommendations (likely patients with
extensive comorbidities who were poor surgical can-
didates), we did not perform additional analyses of
this cohort. In addition, the follow-up durations
differed in the EES and CABG groups due to slower
uptake of EES when the stent was ﬁrst approved.
However, we used time-to-event analysis and there-
fore incorporated the follow-up duration.
CONCLUSIONS
In this largest series of comparison of PCI with a
second-generation DES versus CABG in patients
with CKD, CABG was associated with a higher
short-term risk of death, stroke, and repeat revas-
cularization, whereas PCI with EES was associ-
ated with a higher long-term risk of repeat
revascularization and perhaps MI (in patients who
underwent incomplete revascularization). Howev-
er, in patients on dialysis, the results favored
CABG over PCI. These associations should be
considered when choosing between PCI and CABG
in patients with CKD and should be tested in
future clinical trials.
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